pharma · Myelofibrosis · Acute Myeloid Leukemia
Karyopharm Therapeutics
Karyopharm Therapeutics Inc
Karyopharm Therapeutics is a pharma organization headquartered in Newton, USA. Primary therapeutic focus areas include Myelofibrosis, Acute Myeloid Leukemia, Multiple Myeloma, Thymoma, Myeloma Multiple. NovaPharmaNews li
85 Wells Avenue, Newton, MA 02459, US HQ
313 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 85 Wells Avenue, Newton, MA 02459, US
- Employees
- 313
- Programs
- 82
- Drugs
- 53
- Patents
- 38
Selinexor 60 MG
Phase 2 · small molecule · Multiple Myeloma
Selinexor 60 MG for Multiple Myeloma is a Phase 2 program (small_molecule) at Karyopharm Therapeutics Inc with 1 ClinicalTrials.gov record(s).
Internal code Pro2020-0369
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Karyopharm Therapeutics Inc
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Multiple Myeloma
- Status
- on_hold
- Trials
- 1